MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy. Diagnostic procedures, such as MRI, may help doctors predict whether patients will have heart damage caused by chemotherapy in patients with cancer receiving chemotherapy.
| Condition | Intervention |
|---|---|
|
Cardiac Toxicity Malignant Neoplasm |
Procedure: magnetic resonance imaging |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Early Imaging Detection of Cardiovascular Injury After Cancer |
- To correlate results of an automated MRI hardware/software platform for measuring left ventricular (LV) function with manual results. [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]For the automation to be considered useful it should correlate highly with the manual results, exhibit a similar mean value and overall variability. 95% confidence intervals (CIs) of the difference between measures will be constructed and the upper and lower bounds of these intervals will be examined. The final diagnostic we will perform is to run F-tests to determine whether the variability from each measure is the same or different. 95% CIs will be examined for the ratio of the variance.
- To test the ability of the pre- to post-anthracycline-based chemotherapy (Anth-bC) changes in our MRI platform generated measures of LV function to predict pre- to 24 month post-Anth-bC differences in LV function. [ Time Frame: From baseline to 24 months ] [ Designated as safety issue: No ]Each patient is individually categorized as either having a persistent CV worsening or not depending on whether they exhibit a 20% worsening of their outcome by 3 months and that level of worsening persists to 24 months. We will examine paired t-tests for each time point for each measure to test whether measures are significantly worse at each time point. We will fit longitudinal models that examine all three time points (baseline, 3 and 24 months) simultaneously to determine whether there is a linear (or some other) function that can describe the decline in these subclinical CV MRI measures.
| Estimated Enrollment: | 150 |
| Study Start Date: | January 2013 |
| Estimated Primary Completion Date: | January 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Diagnostic (MRI)
Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
|
Procedure: magnetic resonance imaging
Undergo MRI scans
Other Names:
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To design an automated MRI hardware/software platform for measuring and reporting left ventricular (LV) function (volumes, strain, and ejection fraction [EF]), T1 myocardial signal, and aortic pulse wave velocity (PWV).
II. To determine if pre- to 3 month post-anthracycline-based chemotherapy (Anth-bC) changes in our MRI platform generated measures of LV volumes, EF, strain, myocardial T1, and aortic PWV predict pre- to 24 month post-Anth-bC differences in these same parameters.
OUTLINE:
Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
Eligibility| Ages Eligible for Study: | 22 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Receiving >= 350 mg/m^2 of Anth-bC therapy, or a combination of Anth-bC (>= 250 mg/m^2) and subsequent paclitaxel or Herceptin
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices, or other implanted electronic devices
- Ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal
- Allergy to gadolinium or other severe drug allergies
- Unstable angina
- Significant ventricular arrhythmias (> 20 premature ventricular contractions [PVCs]/minute due to gating difficulty)
- Acute myocardial infarction within 28 days
- Atrial fibrillation with uncontrolled ventricular response
- Moderate or severe aortic stenosis
- Claustrophobia
- Congestive heart failure (New York Heart Association [NYHA] class III or IV)
- Significant valvular disease, or significant pulmonary disease requiring supplemental oxygen therapy
- Participants unwilling to complete the protocol (6 month duration)
- Women who are pregnant
- Patients unable or unwilling to provide informed consent
Contacts and Locations| United States, North Carolina | |
| Comprehensive Cancer Center of Wake Forest University | Recruiting |
| Winston-Salem, North Carolina, United States, 27157 | |
| Contact: William G. Hundley 336-716-6125 ghundley@wfubmc.edu | |
| Principal Investigator: William G. Hundley | |
| Principal Investigator: | William Hundley | Comprehensive Cancer Center of Wake Forest University |
More Information
No publications provided
| Responsible Party: | Comprehensive Cancer Center of Wake Forest University |
| ClinicalTrials.gov Identifier: | NCT01719562 History of Changes |
| Other Study ID Numbers: | CCCWFU 99112, NCI-2012-01613, P30CA012197 |
| Study First Received: | October 11, 2012 |
| Last Updated: | January 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Neoplasms |
ClinicalTrials.gov processed this record on June 18, 2013